Media Center

Media Center

Sandoz TV Episode 18: Trailer

Find out what to expect from the newest episode of Sandoz TV.

Global News Sandoz Around the World Sandoz in the Media

Sandoz Brazil introduces a new option for oncology patients

São Paulo, August 26, 2014

Sandoz, the generic pharmaceutical division of Novartis, today announces the market introduction in Brazil of the first generic version of oncology medicine bortezomibe.

Sandoz receives first approval in Latin America for innovative respiratory inhaler Airflusal® Forspiro®

Holzkirchen, August 20, 2014

Sandoz announces today that the Mexican Health Authority (COFEPRIS) has granted Sandoz marketing authorization for Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Sandoz Germany launches innovative new topical therapy for erectile dysfunction, a leading urological disorder

Holzkirchen, August 18, 2014

Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Germany of Vitaros®, an innovative new topical therapy for erectile dysfunction (ED), one of the leading urological disorders in Europe and worldwide. Earlier this month, Sandoz launched Vitaros in Sweden.

Sandoz Sweden launches innovative new topical therapy for erectile dysfunction, a leading urological disorder

Holzkirchen, August 04, 2014

Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Sweden of Vitaros®, an innovative new topical therapy for erectile dysfunction (ED), one of the leading urological disorders in Europe and worldwide.

FDA accepts Sandoz application for biosimilar filgrastim

Holzkirchen, July 24, 2014

Sandoz, a Novartis Group company, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application for filgrastim.


More News